Millennium Management
IMVT icon

Millennium Management’s Immunovant IMVT Stock Holding History

Millennium Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45,000
Closed -$769K – 6088
2025
Q1 		$769K Buy
+45,000
New +$941K ﹤0.01% 4544
2024
Q2 		– Sell
-15,300
Closed -$494K – 6200
2024
Q1 		$494K Buy
15,300
+400
+3% +$14.6K ﹤0.01% 4820
2023
Q4 		$628K Sell
14,900
-154,400
-91% -$5.68M ﹤0.01% 4508
2023
Q3 		$6.5M Buy
169,300
+53,800
+47% +$1.22M ﹤0.01% 2451
2023
Q2 		$2.19M Buy
+115,500
New +$2.15M ﹤0.01% 3401
2021
Q3 		– Sell
-100,000
Closed -$1.06M – 7001
2021
Q2 		$1.06M Buy
+100,000
New +$1.4M ﹤0.01% 4610

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Millennium Management's IMVT Position: Q1 2026 in Review

Millennium Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 172,496 shares — an estimated $4.38M sold.

Millennium Management first reported a position in IMVT in Q1 2020 and held it in 24 quarters. The position peaked at $28.3M in Q4 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Millennium Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 172,496 Immunovant shares in Q1 2026, an estimated $4.38M.
  • Millennium Management first reported a position in Immunovant in Q1 2020 and held it in 24 quarters.
  • Millennium Management's Immunovant position peaked at $28.3M in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.